On May 15, 2020, Codiak BioSciences, Inc., a company at the forefront of advancing engineered exosomes as a new class of biologic medicines, announced new preclinical data on programs using its proprietary engEx Platform. Highlights included new preclinical data demonstrating the powerful adaptive immune response driven by its exoVACC™ vaccine platform compared to standard vaccine approaches and the first data on Codiak’s ability to utilize engEx to direct tropism for multiple cell types in vitro and in vivo. These data, which were presented at the 23rd Annual Meeting of the American Society of Gene & Cell Therapy (ASCGT) (https://annualmeeting.asgct.org/am20/), demonstrate the broad potential of engineered exosomes to serve as a foundation for new classes of molecular medicines to address complex, immune-mediated diseases. Exosomes are an important intercellular communication system, facilitating the transfer of molecular payloads between cells. They are mediated by a complex network of proteins and glycoproteins on the exosome surface that play a role in cellular tropism, uptake, and immune cell signaling. Utilizing its engEx Platform, Codiak can engineer exosomes with distinct properties, load them with various types of therapeutic molecules and alter tropism so they reach specific cell targets. Codiak is developing exosome product candidates to target multiple pathways throughout the body to treat various forms of cancer and, through its exoVACC modular vaccine platform, to enhance the immune response against a broad array of antigens. “The results that we are generating across our engEx Platform continue to confirm the potential of our engEx-engineered exosomes to be an entirely new modality capable of addressing diseases with unmet needs,” said Douglas E. Williams, PhD, President and Chief Executive Officer of Codiak BioSciences.
Login Or Register To Read Full Story